Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | NQO2 | P16083 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 3/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289511 | 0.98 | MAPT (0.50) | MAPTNPSR1NQO2POLBL3MBTL1 | |
| SCHEMBL1000103 | 0.84 | MAPT (0.58) | MAPTNPSR1NQO2POLBL3MBTL1 | |
| SCHEMBL31211203 | 0.78 | MAPT (0.57) | MAPTNPSR1NQO2POLBL3MBTL1 | |
| SCHEMBL5946197 | 0.78 | MAPT (0.57) | MAPTNPSR1NQO2POLBL3MBTL1 | |
| SCHEMBL2498762 | 0.78 | MAPT (0.52) | MAPTNPSR1NQO2POLBL3MBTL1 | |
| Bromide SCHEMBL15880338 | 0.78 | MAPT (0.47) | MAPTNPSR1NQO2POLBL3MBTL1 | |
| SCHEMBL146892 | 0.77 | ALDH1A1 (0.58) | MAPTNQO2POLBGAAALOX15 | |
| SCHEMBL24722948 | 0.76 | HPGD (0.40) | MAPTPOLBL3MBTL1GAAALDH1A1 | |
| SCHEMBL5161298 | 0.76 | MAPT (0.43) | MAPTNPSR1POLBL3MBTL1GAA | |
| SCHEMBL30700955 | 0.76 | ALDH1A1 (0.59) | MAPTNPSR1POLBL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042879-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| CN-118843625-A | Heterocyclically substituted 1,3, 4-thiadiazole and pyridazine compounds and methods of use thereof | 亚根达医疗公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4436665-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023092149-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-9108936-B2 | Substituted 4-aminobenzamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| EP-2844645-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-03-11 | — | — | EP | disclosed |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| WO-2013156155-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042879-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | RBM17, SF3B5, SF3A2 | MAPT 4519/4885NPSR1 2771/4885NQO2 1119/4885 |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | KCNJ2, KCNQ2, KCNQ1 | MAPT 3816/4885NPSR1 1619/4885NQO2 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.